Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
NurExone Biologic Inc. (NRXBF) had Non-Operating Income/Expense of $-0.06M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$0.70M |
|
-- |
|
-- |
|
$-0.76M |
|
$0.76M |
|
|
Non-Operating Income/Expense |
$-0.06M |
$0.70M |
|
$0.70M |
|
$0.70M |
|
$0.70M |
|
$0.70M |
|
$0.70M |
|
$0.76M |
|
$0.80M |
|
65.42M |
|
65.42M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$1.63M |
|
$0.76M |
|
$0.81M |
|
$2.44M |
|
$0.40M |
|
-- |
|
$0.28M |
|
$0.68M |
|
$1.76M |
|
$1.76M |
|
$1.76M |
|
71.07M |
|
| Cash Flow Statement Financials | |
$-4.89M |
|
$-0.66M |
|
$5.88M |
|
$0.54M |
|
$0.70M |
|
$0.16M |
|
$0.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
39.81% |
|
39.81% |
|
28.72% |
|
39.81% |
|
$0.02 |
|
$-0.08 |
|
$-0.07 |
|